IceCure Medical Announces Strategic Deal With Terumo

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

IceCure Medical Ltd. is a developer of the next generation cryoablation technology to treat malignant and benign tumors by freezing without the need for surgery. Today the company announced they entered into an exclusive distribution agreement with leading global medical company, Terumo Corporation (Tokyo: 4543, TRUMY: OTC US). The new agreement will accelerate the commercialization of its ProSense™ cryoablation system and associated consumables to treat malignant breast tumors in Japan and Singapore.

  • Under the terms of the agreement, in exchange for granting exclusive distribution rights and obtaining regulatory approvals for ProSense™ and its consumables, Terumo will commit up to USD $2 million. This will include a one-time, up-front payment of USD $1 million to IceCure 30-days after signing the agreement and the remainder in milestones.
  • The agreement also comprises Terumo’s undertaking to purchase 10 ProSense™ system consoles and consumables at the time of signing for use in clinical trials to support regulatory filing.
  • Terumo will also be responsible for, and incur costs for, obtaining all regulatory approvals and insurance indemnifications in Japan, with regulatory rights owned by Terumo.  Initial regulatory approval is anticipated in Japan in a few years.

Eyal Shamir, IceCure’s CEO, stated, “We are excited to partner with Terumo, a leading global medical company, in this milestone agreement. With Terumo’s proven medical distribution network and the necessary sales and marketing expertise, this new partnership will support rapid commercialization of our cryoablation solution in Japan and Singapore, pending regulatory approval.”

“The ProSense™ system has already demonstrated excellent progress as a rapid, in-office solution for the treatment of breast tumors.  With its expanding clinical data as a non-surgical alternative to treat cancer, the innovative ProSense™ system makes an exciting addition to our portfolio to address key unmet needs and improve patient outcomes,” said Tsuyoshi Tomita, Group Manager, General Hospital Products Group, Terumo Corporation.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.